search
Back to results

Effect of Home Rehabilitation on State of Patients With PAH, HFREF and IHD

Primary Purpose

Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Ischemic Heart Disease

Status
Completed
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
home cardiac rehabilitation and respiratory rehabilitation
Sponsored by
Medical University of Bialystok
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Pulmonary Hypertension focused on measuring cardiac rehabilitation, pulmonary rehabilitation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • age >18 years
  • informed consent signed by patient to conduct the study
  • no diseases excluding rehabilitation
  • pts with idiopathic, inherited PAH (pulmonary arterial hypertension), or in the course of connective tissue diseases, portal hypertension, congenital heart diseases.
  • PAH confirmed in catheterisation of right side of heart mPAP (mean pulmonary arterial pressure) ≥25 mmHg, PCWP (pulmonary capillary wedge pressure) ≤15mmHg.
  • Chronic heart failure - left ventricle ejection fraction <40% in echocardiography, NYHA *New York Health Association) class II-III
  • stable ischaemic heart disease in CCS (Canadian Cardiovascular Society) class II-III

Exclusion Criteria:

  • Other types of pulmonary hypertension
  • COPD (chronic obstructive pulmonary disease), asthma
  • malignancies
  • Acute inflammatory state up to 4 weeks before inclusion to the study
  • Acute coronary syndrome up to 3 months before inclusion to the study
  • Heart failure in NYHA IV class
  • severe anaemia (Hgb <11g/dl for men <10g/dl for women)
  • electrolyte and hormonal disturbances in period of 1 month before inclusion to the study
  • substantial modification of treatment of main disease within last 3 months
  • ischaemic heart disease in CCS class IV
  • Other clinical situations excluding to perform controlled program of rehabilitation

Sites / Locations

  • Medical University of Bialystok, Department of Rehabilitation

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

No Intervention

Arm Label

Patients with PAH

Patients with HFREF

Patients with IHD

Control group

Arm Description

home cardiac rehabilitation and respiratory rehabilitation

home cardiac rehabilitation and respiratory rehabilitation

home cardiac rehabilitation and respiratory rehabilitation

No rehabilitation

Outcomes

Primary Outcome Measures

Clinical improvement assesment of 6 MWT distance
6-min walk test (6 MWT) is a exercise test that entails measurement of distance walked over a span of 6 minutes by patient good outcome > 500 m, bad outcome < 200 m

Secondary Outcome Measures

Evaluation of quality of life
Quality of life measurement with SF36 (The Short Form (36) Health Survey, which is a 36-item, patient-reported survey of patient health.The Optum™ SF-36v2® Health Survey asks 36 questions to measure functional health and well-being from the patient's point of view. It is a practical, reliable and valid measure of physical and mental health that can be completed in five to ten minutes. The more number of points witness of better quality of life. Scores are calibrated so that 50 is the average score or norm. This norm-based score allows comparison among the three surveys and across the more than 19,000 studies published in the past 20 years. This bibliography includes studies of hundreds of diseases, conditions and populations, and greatly enhances the ability to interpret SF health survey data in new studies.
Force of respiratory muscles
measurement of maximal inspiratory and expiratory pressure
Clinical improvement - evaluation of WHO class
Patients' functional status is assessed with use of World Health Organisation (WHO) for pulmonary arterial hypertension. Best status is class I, worst status is class IV
Evaluation of NYHA class
Patients' functional status is assessed with use of New York Heart Association (NYHA) classification for heart failure, best status is class I, worst status is class IV.
Evaluation of CCS class
Patients' functional status is assessed with use of Canadian Cardiovascular Society (CCS) classification for coronary artery disease. Best status is class I, worst status is class IV

Full Information

First Posted
September 13, 2018
Last Updated
October 23, 2021
Sponsor
Medical University of Bialystok
search

1. Study Identification

Unique Protocol Identification Number
NCT03780803
Brief Title
Effect of Home Rehabilitation on State of Patients With PAH, HFREF and IHD
Official Title
Evaluation of Influence of Home Physical Training Program and Respiratory Rehabilitation on Quality of Life, Body Composition, and Function of Respiratory Muscles in Patients With Primary PAH, HFREF and IHD
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
February 1, 2016 (Actual)
Primary Completion Date
September 30, 2021 (Actual)
Study Completion Date
September 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Bialystok

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the study is to evaluate the influence of physical training and respiratory rehabilitation performed by patients at home on quality of life, symptoms, physical endurance, force of respiratory and skeletal muscles and body mass composition in patients with pulmonary arterial hypertension (PAH) or left ventricular heart failure with reduced ejection fraction - HFREF), or ischemic heart disease and evaluation the number of stem cells, natural lymphoid cells and distribution of subpopulations of monocytes (including proangiogenic monocytes) in examined persons and evaluation of theirs eventual influence of the course of disease.
Detailed Description
The study will be conducted on total group of 100 participants, from which 75 will be the patients with PAH (pulmonary arterial hypertension), HF-REF (heart failure with reduced ejection fraction) or IHD (ischemic heart disease). In all participants medical anamnesis, physical examination, anthropometric measures, 6-minute walking distance (6MWD six minute walking distance) will be performed and initial functional class according WHO (World Health Organisation)/NYHA (New York Health Association)/CCS (Canadian Cardiovascular Society) classification will be evaluated. Medical history will consist of questions regarding coexisting diseases, treatment, lifestyle, family burden, etc. Quality of life will be assessed with use of The Short Form (36) Health Survey - SF-36) and Fatigue Severity Scale - FSS. Biochemical measures will be performed including, among others. brain natriuretic peptide (BNP), blood morphology, P-selectin, concentrations of cytokines such as : Interleukin 6 (IL-6), soluble Interleukin 6 receptor (sIL-6R), stromal derived factor-1 (SDF-1, CXCL12) and soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK). Among lab parameters routinely measured in groups of patients with PAH, HFREF, IHD performed in Cardiology Department of University Clinical Hospital during hospitalization will be used: creatinine level, uric acid level, total cholesterol, LDL (low density lipoprotein), HDL (high density lipoprotein), triglycerides levels, troponin I level, CRP (C reactive protein), BNP (brain natriuretic peptide), fasting glucose, TSH (thyroid stimulating hormone), blood morphology and arterial geometry. Fasting venous blood will be collected in 4 tubes each a 10 ml. Two tubes a 10ml (one dedicated to obtain serum ("on clot"), second with heparin) to perform biochemical analyses, tube a 10ml with EDTA (ethylenediaminetetraacetic acid) will be used to evaluate PBMC (peripheral blood mononuclear cell) (density gradient centrifugation), tube a 10ml with citrate will be used to obtain platelet lysate. Additionally fasting venous blood will be obtained - 2 tubes a 10ml in order to assess number of stem cells, natural lymphoid cells, and distribution of subpopulations of lymphocytes. In clinical evaluation measurement of respiratory (inspiratory and expiratory) muscles force with use of device MicroRPM (respiratory pressure meter), analysis of body mass composition with special regard to muscular mass with use of bioelectrical impedance analysis method (BIA) (Maltron) and measurement of hand grip strength with use of hand dynamometer will be performed. During first visit also ECG (electrocardiogram) and echocardiography will be done. The safe protocol of home physical training and respiratory rehabilitation adjusted to the clinical state of patients will be developed in the form of brochure with photos and precise description of exercises and the diary of self-control of patient in order to collect data regarding daily physical activity will be given to participants. Patients willing to take part in stage of exercises (circa 45 persons) will be trained in Rehabilitation Department how to perform exercises at homes. Easy to use devices dedicated to respiratory exercises (Pulmogain Respitrain) enabling respiratory muscles training with various degree of intensity and pedometers to assess daily motor activity will be given to patients. Stage of exercises during which the next series of tests will be performed will last 6 months. Exercising patients will come to Rehabilitation Department on first and third month after start of rehabilitation in order to control the correctness of training performance, filling self-control diary assessment of patients compliance and eventual corrections of training program. Patients will be also under continuous phone supervision (minimally once a week) and in the case of doubts and need for consultation. After finishing exercises stage and performed clinical evaluation, patients will by themselves decide if they are willing to continue rehabilitation (will have possibility of further use of physiotherapists care), and follow up assessment will take place after 6 months from finishing exercises stage. Comparative group will consist of patients with PAH, HF-REF, IHD who agreed to participate in study but were not qualified to the exercises stage. Control group will consist of patients of Cardiology Department and Cardiology Outpatient Clinic and Rehabilitation Department (without cardiovascular diseases). Range of examinations in control group will consists of medical anamnesis, physical examination, anthropometric measures, individually filled questionnaires SF-36 and FSS, evaluation of respiratory muscles force, hand grip strength and analysis of body mass composition BIA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Ischemic Heart Disease
Keywords
cardiac rehabilitation, pulmonary rehabilitation

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
93 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Patients with PAH
Arm Type
Experimental
Arm Description
home cardiac rehabilitation and respiratory rehabilitation
Arm Title
Patients with HFREF
Arm Type
Experimental
Arm Description
home cardiac rehabilitation and respiratory rehabilitation
Arm Title
Patients with IHD
Arm Type
Experimental
Arm Description
home cardiac rehabilitation and respiratory rehabilitation
Arm Title
Control group
Arm Type
No Intervention
Arm Description
No rehabilitation
Intervention Type
Other
Intervention Name(s)
home cardiac rehabilitation and respiratory rehabilitation
Primary Outcome Measure Information:
Title
Clinical improvement assesment of 6 MWT distance
Description
6-min walk test (6 MWT) is a exercise test that entails measurement of distance walked over a span of 6 minutes by patient good outcome > 500 m, bad outcome < 200 m
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Evaluation of quality of life
Description
Quality of life measurement with SF36 (The Short Form (36) Health Survey, which is a 36-item, patient-reported survey of patient health.The Optum™ SF-36v2® Health Survey asks 36 questions to measure functional health and well-being from the patient's point of view. It is a practical, reliable and valid measure of physical and mental health that can be completed in five to ten minutes. The more number of points witness of better quality of life. Scores are calibrated so that 50 is the average score or norm. This norm-based score allows comparison among the three surveys and across the more than 19,000 studies published in the past 20 years. This bibliography includes studies of hundreds of diseases, conditions and populations, and greatly enhances the ability to interpret SF health survey data in new studies.
Time Frame
6 months
Title
Force of respiratory muscles
Description
measurement of maximal inspiratory and expiratory pressure
Time Frame
6 months
Title
Clinical improvement - evaluation of WHO class
Description
Patients' functional status is assessed with use of World Health Organisation (WHO) for pulmonary arterial hypertension. Best status is class I, worst status is class IV
Time Frame
6 months
Title
Evaluation of NYHA class
Description
Patients' functional status is assessed with use of New York Heart Association (NYHA) classification for heart failure, best status is class I, worst status is class IV.
Time Frame
6 months
Title
Evaluation of CCS class
Description
Patients' functional status is assessed with use of Canadian Cardiovascular Society (CCS) classification for coronary artery disease. Best status is class I, worst status is class IV
Time Frame
6 months
Other Pre-specified Outcome Measures:
Title
Body mass composition in patients with PAH
Description
Bioelectrical impedance analysis of body mass composition- body fat (amount of body fat in kilograms), body fat (amount of body fat percentage), body muscle content (amount of body muscles in kilograms), body muscle content (amount of body muscles percentage), water content (amount of water in kilograms), water content (amount of water percentage), organic substances content (amount of organic substances in kilograms), organic substances content (amount of organic substances percentage).
Time Frame
6 months
Title
Weight
Description
measurement of weight in kilograms
Time Frame
6 months
Title
Concentration of BNP (brain natriuretic peptide)
Description
Biochemical analyses - serum concentrations of brain natriuretic peptide (BNP) pg/ml
Time Frame
6 months
Title
Concentration of creatinine
Description
Measurement of serum concentrations of creatinine mg/dl
Time Frame
6 months
Title
Concentration of uric acid
Description
Measurement of serum concentrations of uric acid mg/dl
Time Frame
6 months
Title
Concentration of total cholesterol
Description
Measurement of serum concentrations of total cholesterol mg/dl
Time Frame
6 months
Title
Concentration of LDL
Description
Measurement of serum concentrations of LDL (low density lipoprotein) mg/dl
Time Frame
6 months
Title
Concentration of HDL
Description
Measurement of serum concentrations of HDL (high density lipoprotein) mg/dl
Time Frame
6 months
Title
Concentration of triglycerides
Description
Measurement of serum concentrations of triglycerides mg/dl
Time Frame
6 months
Title
Concentration of CRP
Description
Measurement of serum concentrations of CRP (C-reactive protein) mg/dl
Time Frame
6 months
Title
Concentration of fasting glucose
Description
Measurement of serum concentrations of fasting glucose mg/dl
Time Frame
6 months
Title
Activity of TSH
Description
Measurement of serum activity of TSH mU/l,
Time Frame
6 months
Title
Concentration of Troponin I
Description
Measurement of serum concentrations of troponin I µg/l,
Time Frame
6 months
Title
Number of WBC
Description
Measurement of number of WBC (white blood cells) K/µl,
Time Frame
6 months
Title
Number of RBC
Description
Measurement of number of RBC (red blood cells ) M/µl
Time Frame
6 months
Title
Concentration of Hemoglobin
Description
Measurement of serum concentrations of Hgb (hemoglobin) g/dl
Time Frame
6 months
Title
Concentration of P selectin
Description
Measurement of serum concentrations of P selectin, ng/ml
Time Frame
6 months
Title
Concentration of Il-6
Description
Measurement of serum concentrations of interleukin 6 (IL-6) pg/ml
Time Frame
6 months
Title
Concentration of sIl-6 R
Description
Measurement of serum concentrations of soluble Interleukin 6 receptor (sIL-6R),ng/ml
Time Frame
6 months
Title
Concentration of SDF-1
Description
Measurement of serum concentrations of stromal derived factor-1 (SDF-1, CXCL12), ng/ml
Time Frame
6 months
Title
Concentration of sTWEAK
Description
Measurement of serum concentrations of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK). pg/ml
Time Frame
6 months
Title
Percentage of stem cells
Description
assesment of amount of stem cells (percentage of undifferentiated cells)
Time Frame
6 months
Title
percentage of subpopulations of monocytes
Description
profile of subpopulations of monocytes (percentage)
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: age >18 years informed consent signed by patient to conduct the study no diseases excluding rehabilitation pts with idiopathic, inherited PAH (pulmonary arterial hypertension), or in the course of connective tissue diseases, portal hypertension, congenital heart diseases. PAH confirmed in catheterisation of right side of heart mPAP (mean pulmonary arterial pressure) ≥25 mmHg, PCWP (pulmonary capillary wedge pressure) ≤15mmHg. Chronic heart failure - left ventricle ejection fraction <40% in echocardiography, NYHA *New York Health Association) class II-III stable ischaemic heart disease in CCS (Canadian Cardiovascular Society) class II-III Exclusion Criteria: Other types of pulmonary hypertension COPD (chronic obstructive pulmonary disease), asthma malignancies Acute inflammatory state up to 4 weeks before inclusion to the study Acute coronary syndrome up to 3 months before inclusion to the study Heart failure in NYHA IV class severe anaemia (Hgb <11g/dl for men <10g/dl for women) electrolyte and hormonal disturbances in period of 1 month before inclusion to the study substantial modification of treatment of main disease within last 3 months ischaemic heart disease in CCS class IV Other clinical situations excluding to perform controlled program of rehabilitation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karol Kamiński, Professor
Organizational Affiliation
Medical University of Bialystok
Official's Role
Study Chair
Facility Information:
Facility Name
Medical University of Bialystok, Department of Rehabilitation
City
Białystok
State/Province
Podlaskie
ZIP/Postal Code
15-089
Country
Poland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28099988
Citation
Morris NR, Kermeen FD, Holland AE. Exercise-based rehabilitation programmes for pulmonary hypertension. Cochrane Database Syst Rev. 2017 Jan 19;1(1):CD011285. doi: 10.1002/14651858.CD011285.pub2.
Results Reference
background
PubMed Identifier
16982941
Citation
Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grunig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006 Oct 3;114(14):1482-9. doi: 10.1161/CIRCULATIONAHA.106.618397. Epub 2006 Sep 18.
Results Reference
background
PubMed Identifier
23962982
Citation
Zafrir B. Exercise training and rehabilitation in pulmonary arterial hypertension: rationale and current data evaluation. J Cardiopulm Rehabil Prev. 2013 Sep-Oct;33(5):263-73. doi: 10.1097/HCR.0b013e3182a0299a.
Results Reference
background
PubMed Identifier
24771460
Citation
Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, Lough F, Rees K, Singh S. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014 Apr 27;2014(4):CD003331. doi: 10.1002/14651858.CD003331.pub4.
Results Reference
background
PubMed Identifier
25685361
Citation
Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal HM, Lough F, Rees K, Singh S, Taylor RS. Exercise-based rehabilitation for heart failure: systematic review and meta-analysis. Open Heart. 2015 Jan 28;2(1):e000163. doi: 10.1136/openhrt-2014-000163. eCollection 2015.
Results Reference
background
PubMed Identifier
23013125
Citation
Oldridge N. Exercise-based cardiac rehabilitation in patients with coronary heart disease: meta-analysis outcomes revisited. Future Cardiol. 2012 Sep;8(5):729-51. doi: 10.2217/fca.12.34.
Results Reference
background
PubMed Identifier
21735386
Citation
Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, Thompson DR, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD001800. doi: 10.1002/14651858.CD001800.pub2.
Results Reference
background
PubMed Identifier
34321095
Citation
Wojciuk M, Ciolkiewicz M, Kuryliszyn-Moskal A, Chwiesko-Minarowska S, Sawicka E, Ptaszynska-Kopczynska K, Kaminski K. Effectiveness and safety of a simple home-based rehabilitation program in pulmonary arterial hypertension: an interventional pilot study. BMC Sports Sci Med Rehabil. 2021 Jul 28;13(1):79. doi: 10.1186/s13102-021-00315-y.
Results Reference
derived
Links:
URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316895/
Description
Effectiveness and safety of a simple home-based rehabilitation program in pulmonary arterial hypertension: an interventional pilot study

Learn more about this trial

Effect of Home Rehabilitation on State of Patients With PAH, HFREF and IHD

We'll reach out to this number within 24 hrs